-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Citius Oncology, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2023 to 2024.
- Citius Oncology, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending December 31, 2024 was $264K, a 83.5% increase year-over-year.
- Citius Oncology, Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was $576K, unchanged from 2023.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)